Clinical Trial

QA108 Phase III Study in Subjects With Intermediate AMD

Name: QA108 Phase III Study in Subjects With Intermediate AMD — clinical trial record (NCT07189169)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Phase 3

View on ClinicalTrials.gov →

Summary

This is a phase III randomized, double-masked, placebo-controlled, multicenter study. To evaluate the efficacy and safety of QA108 granules in the treatment of intermediate age-related macular degeneration.

Trial Details

NCT Number	NCT07189169
Lead Sponsor	Smilebiotek Zhuhai Limited
Conditions	Intermediate Age-Related Macular Degeneration
Enrollment	400 participants
Start Date	2025-07-08
Primary Completion	2027-03-01 (estimated)
Study Completion	2027-06-30 (estimated)
Updated on ClinicalTrials.gov	2025-09-23